Multiplexed Ion Bean Imaging Microscopy to support Digital Pathology in experimental medicine studies

新疗法在早期药物发现阶段未能成功的最常见原因是它们不安全，而不是非常有效。我们现在知道原因了。这是因为如何证明药物被认为干扰的药物途径已经进入了接受药物治疗的人体组织，这是一个悬而未决的问题。我们认为这是因为我们对如何将被测试的药物与组织中细胞的位置联系起来还没有充分的了解。通过使用一种名为MIBI成像的新型显微镜，我们的目标是为经典组织学提供一种颠覆性的方法，就像核磁共振成像的出现在放射学中为普通胶片X射线所做的那样。我们称这种新型组织学为数字病理学，如果这笔资金得到资助，我们将成为英国第一个能够使用MIBI显微镜的单位。

The most common reason why new treatments to not make it during the early phase drug discovery is that they are not safe but rather that they are not very effective. We now know why. Its due to the unsolved problem of how to show that the drug pathways that the drugs are thought to interfere with have been engaged in the tissues of humans treated with the medicines. We propose that this is because we do not have a sufficiently developed understanding of how to link the drugs being tested to the location of cells in tissues. By using a new type of microscopy called MIBI imaging we aim to provide as disruptive an approach to classical histology as the advent of MRI imaging did for plain film X rays in radiology. We call this new type of histology Digital Pathology and if this grant is funded, we will be the first unit in the UK to have access to the MIBI microscope.